


## What is The Aim of HDClarity?

#### **TO ADVANCE HD RESEARCH**


**COLLECT:** We are building a collection of high-quality cerebrospinal fluid (CSF), plasma and serum samples across 8 study groups:



CSF is an ideal fluid compartment for assessing HD biomarkers, particularly pharmacodynamic markers, due to its proximity to the brain. High quality plasma and serum samples are also collected matching the CSF collections, which will be used to evaluate biomarkers and pathways of relevance to HD research.

### What Does HDClarity Participation Involve?

Participants will attend annually and take part in two visits (Screening and Sampling) within a 30-day window. Some may attend an optional Repeat Sampling visit 4-8 weeks later:



HDClarity samples are processed, logged and deposited for long-term storage at BioRep s.r.l. For more information, please see Poster "Enroll-HD Platform Biosample Resources".

**DISTRIBUTE:** Samples can be requested by investigators around the world, allowing them to conduct groundbreaking research to identify new biomarkers and develop treatments for HD.

To request HDClarity samples for your research please see information at https://enroll-hd.org/for-researchers/access-data-biosamples.

#### **How Safe Is HDClarity Participation?**

Very safe! A recent study found that after nearly **600** spinal the most common side effect is a mild or moderate headache, which soon gets better! Only I severe adverse event was reported, corresponding to **0.17%** of the total number of sampling visits!

#### How Can I Get Involved In HDClarity?

**Sites –** if you would like to join as a study site, please contact HDClarity Central Coordination (HDClarity-CC@enroll-hd.org).

**Participants –** you must already be participating in Enroll-HD and can speak to your site staff.

HDClarity

A multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington's disease 10-14 months

In total, we hope to enroll **2500** individuals.

## How Many HDClarity Visits Have Been Conducted So Far?

In total, we have completed **796** Screening visits

709 Sampling visits, and

**101** Optional Repeat Sampling visits.

Total HDClarity Visits per Site Baseline and Longitudinal Visits Included

Screening Sampling RPT Sampling

**Clinical Site** 


For more detailed HDClarity information, search for the study on the NIH clinical trials website. View our dedicated study homepage and follow us on twitter for regular study updates!



We would like to thank all the clinical sites and most importantly, the HD community, whose dedication and perseverance is vital to the success of HDClarity. April 17, 2023

# Where Are HDClarity Sites Located?

HDClarity has continued to expand and is now operational in **31** clinical sites, across **8** nations worldwide. We are actively working to commence the study at more sites across Australasia, Europe and North America.



#### How are HDClarity Samples Being Used in Research?

Biosamples have been distributed for more than 25 research projects.



To find out more about some of the work, please visit the following posters: Natallia Kalinava (CHDI Management Inc./CHDI Foundation) Poster #99 William J Griffiths (Swansea University) Poster #101

There will be more information about HDClarity samples in the "Biofluid and imaging biomarkers: from discovery to clinical validation" Session Niels Henning Skotte, PhD, University of Copenhagen "Biofluid biomarker discovery in HD – Current possibilities and limitations" William J Griffiths, PhD, Swansea University "Cholesterol and oxysterols as biomarkers for Huntington's disease?"

Recently, HDClarity samples have been used in a "SomaLogic Analysis" allowing scientists to measure more than **7000** proteins in CSF. This is an amazing achievment and a huge step forward for the discovery of new biomarkers! This data set is available upon request through the Enroll website.

Chief Investigator: Professor Edward Wild, MD PhD
CHDI Clinical Research Program Manager and Study Lead: Elena Pak
CHDI Clinical Wet Biomarkers Unit Lead: Hilary Wilkinson, PhD
CHDI Chief Medical Officer: Cristina Sampaio, MD PhD

HDClarity is sponsored by University College London, coordinated by UCL Huntington's Disease Centre and funded by CHDI Foundation, Inc. Study Website: https://HDClarity.net Clinical Study Homepage: https://clinicaltrials.gov Twitter Handle: @HDClarityStudy